Saturday, February 11, 2012

SGLT2 inhibitors -- an upcoming class of medications for diabetes

Sodium-glucose transporter-2 (SGLT2) is the name of a "transporter protein" in the kidneys that has become a hot topic in diabetes research. In people with normal blood glucose (BG) levels, glucose is not excreted into the urine, but thanks to SGLT2, remains in the body. Which is a good thing: gluc...
3/18/09 5:21pm

interesting post- i found the Mg results the most intriguing- magnesium deficiency has been implicated in the etiology of insulin resistance- and the suspected process is via urinary losses- studies have shown that higher Mg intake can increase insulin sensitivity, but from this post idea, decreasing urinary losses of Mg might also work to increase insulin sensitivity- and i've also wondered if there's any link between chronic diuretic use and insulin resistance, via the same process of increased Mguria

3/26/09 6:24am

Loss of glucose from the urine could lead to a continued high concentration of glucose in the kidneys. would it lead to excessive glycation of kidney proteins and thereby damage of kidneys

3/26/09 7:16am

You identify one of zillions of conceivable issues with this new class of drugs; at this moment I have no idea, but it would seem likely that your question won't be answered until big studies are done that last a longer time, or perhaps until the drug has been on the market for several years.

 

Which, of course, is why the FDA and other regulatory authorities in other countries require large trials (called Phase III trials) that last at least a year before they will consider approving a drug for general use. And why they require continuing surveillance after they're approved.

 

Good question!

1/18/11 11:13am

 Dr.Q, very well put & hope all can appreciate some further supporting data that clarifies some much wanted answerd questions... enjoy the indepth read...on Apple Trees to Sodium Glucose Co-Transporter Inhibitors: A Review of SGLT2 Inhibition

 

http://clinical.diabetesjournals.org/content/28/1/5.full.pdf

 

http://clinical.diabetesjournals.org/content/28/1/5.full
 

7/24/11 11:34am

I've written another SharePost about one of the SGLT-2 inhibitors: dapagliflozin. The FDA's Advisory Committee has voted against its approval because of safety concerns. See Dapagliflozin, a New Drug for T2D, Rejected by an FDA Advisory Committee.

Ask a Question

Get answers from our experts and community members.

Btn_ask_question_med
View all questions (3731) >